Huawei’s health ambitions are moving beyond the smartwatch. At the European Society of Cardiology Congress (ESC) in Munich, the Chinese technology group unveiled Terve Research, a platform designed to connect its growing base of wearable users with medical researchers and turn everyday health data into a potential source of real-world evidence.
Funded by Huawei but independently managed and operated by European medical technology provider Thryve, the platform is designed to connect academic and medical institutions with Huawei wearable users, allowing researchers to recruit participants and collect longitudinal health data outside conventional clinical settings.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The proposition addresses one of the persistent challenges in digital health research: scale.
Recruiting sufficiently large cohorts and repeatedly measuring participants can be costly and time-consuming. A wearable already being used in everyday life offers a different possibility – continuous data collected as people sleep, exercise and go about their daily routines.
Eligible Huawei users will be able to voluntarily discover and join open studies through the Terve Research app, while researchers can also run closed recruitment programmes. Participants must opt in before their data is collected for research.
The first two studies are due to launch in September. One, led by Professor Ramin Khatami of University Hospital Zurich, will examine the relationship between irregular sleep patterns and cardiovascular and metabolic health. The second, led by Professor Tomasz Guzik, chair of the programme committee at the ESC, will investigate links between physical activity and cardiovascular risk.
Building a European research ecosystem
For Huawei, however, Terve Research is about more than two studies. It is part of a broader effort to connect the company’s wearable hardware with medical research, longitudinal health data and artificial intelligence – and to move closer to the infrastructure of Europe’s expanding digital health ecosystem.
The strategy builds on Huawei’s substantial global wearable footprint. According to the company, it has shipped more than 200 million wearable devices worldwide and has more than 620 million users, with over 125 million monthly active users. Its TruSense health-sensing system supports more than 70 health and fitness indicators, and Huawei claims it secured 46 medical-device registration certificates globally by the end of 2025.
The Chinese group has spent years building research capabilities around its devices, with programs spanning cardiovascular disease, arrhythmia, stroke, blood pressure, blood glucose and metabolic health. Huawei’s Helsinki Health Lab completed 30 collaborative projects and contributed to four EU initiatives in 2025.
For researchers, access to a large established user base could potentially make it easier to recruit participants and collect repeated measurements outside conventional clinical environments.
From ‘snapshot medicine’ to continuous monitoring
The European research push reflects a wider evolution in wearable technology. Devices that began primarily as fitness and wellness products are increasingly being positioned as tools for continuous health monitoring and research.
Dr Zhou Hong, President of the Huawei European Research Institute, emphasised the potential of continuous monitoring and the fusion of multiple data streams from smart wearables to provide a more comprehensive picture of an individual’s health than episodic clinical measurements.
The potential value, he argued, lies not simply in collecting more information, but in applying artificial intelligence (AI) to interpret it. Advanced algorithms can translate multiple physiological signals into personalised health insights for users, while also providing physicians with longitudinal information that could support more informed clinical decisions.
The approach could help bridge the gap between sporadic medical check-ups and proactive health management, particularly as wearables increasingly capture information across different aspects of daily life, from sleep and physical activity to cardiovascular indicators.
That shift was a central theme of Huawei’s discussion at ESC, where specialists in hypertension, sleep and exercise examined the potential value of longitudinal data.
Professor George Stergiou, a leading hypertension specialist, challenged the conventional tendency to dismiss fluctuations in physiological measurements as “noise”.
“It is not noise. It’s information,” he said, emphasising that the distinction is important. Conventional healthcare often relies on measurements taken at particular moments – a blood-pressure reading in a doctor’s office, for example, or a sleep assessment conducted over a limited period. Wearables can potentially provide a much longer view of an individual’s health, capturing changes during everyday activities, sleep, exercise and periods of stress.
Professor Khatami described the potential transformation as a move from “snapshot medicine to long-term medicine to behaviour medicine”.
For researchers, access to continuous real-world data could improve the ability to identify patterns and changes that are difficult to capture through conventional clinical studies. For healthcare providers, the longer-term ambition is to use those insights to support earlier intervention and more personalised approaches to prevention and disease management.
Turning more data into clinical value
AI is likely to become increasingly important as this model develops. As wearables generate greater volumes of physiological information, the challenge shifts from collecting data to determining which changes are clinically meaningful and how those findings should be presented to patients and healthcare professionals.
That could create opportunities beyond research. Personalised analysis may allow interventions to be informed by an individual’s own longitudinal health history rather than population averages, while automated monitoring could eventually support virtual care models and help healthcare systems manage larger patient populations.
But more data does not automatically mean better healthcare.
Huawei’s research strategy is increasingly moving into more specialised health applications. Alongside Terve Research, the company unveiled the HUAWEI WATCH D3 at ESC, featuring CE-marked blood-pressure monitoring capabilities, including ambulatory and pre- and post-exercise measurements. The device becomes globally available on September 2.
The move towards medical applications raises questions around clinical validation, measurement accuracy, data governance and user consent. The credibility of wearable-generated health data will ultimately depend on whether measurements can demonstrate sufficient reliability and clinical relevance for the particular use case.
There is also a practical challenge for healthcare systems. Clinicians already face growing volumes of information and limited time to interpret it.
As Professor Stergiou put it: “Doctors do not have time. Don’t ask them for more time.”
That may prove to be one of the defining tests for the next phase of digital health. The value of wearable technology will depend not simply on how much data devices can collect, but on whether that data can be converted into reliable, clinically meaningful and actionable information without increasing the workload of already stretched healthcare professionals.
